TransCode Therapeutics Sees Major Shareholder DEFJ Convert Preferred Stock, Diluting Equity as Capital Repositions for Future Growth
DEFJ’s conversion of TransCode’s preferred shares into common stock unlocks liquidity but dilutes equity; investors weigh capital use vs. price impact.
3 minutes to read